Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Beats on EPS, Stock Down 4.28%

Alnylam Pharmaceuticals reported a strong earnings per share figure, exceeding expectations significantly. However, the stock fell by 4.28% in reaction to the earnings report, indicating that investors may have been disappointed by the lack of revenue information and guidance. The absence of management commentary may have also contributed to the negative stock movement.